As reported on Healio, glucagon-like peptide-1 (GLP-1) receptor agonists, best known for treating diabetes and obesity, are emerging as unexpected players in breast cancer care. Data presented at the recent San Antonio Breast Cancer Symposium (SABCS) suggest these agents may be associated with improved survival, reduced recurrence, and better treatment tolerability among people with breast cancer. Although the findings remain preliminary and largely retrospective, oncologists describe the signals as compelling and worthy of rigorous prospective study.
From metabolic disease to oncology
GLP-1 receptor agonists have been part of diabetes management for two decades and were later approved for obesity, a condition now recognized as a major modifiable cancer risk factor. These drugs improve glycemic control, reduce systemic inflammation, and enhance insulin sensitivity—biologic processes increasingly linked to cancer initiation and progression.
Earlier research has hinted at a protective role for GLP-1s against obesity-related malignancies, and real-world data in hematologic cancers have associated their use with lower mortality and fewer cardiovascular complications. At SABCS, investigators extended this line of inquiry to breast cancer, presenting multiple retrospective analyses across disease stages and subtypes.
Survival and recurrence: encouraging associations
Several studies focused on whether GLP-1 exposure correlates with improved breast cancer outcomes.
One analysis evaluated patients with ductal carcinoma in situ (DCIS) receiving endocrine therapy. Using a large real-world database and propensity score matching, researchers compared outcomes between GLP-1 users and nonusers. Over five years, those exposed to GLP-1s experienced substantially lower rates of invasive or metastatic recurrence and improved overall survival.
Another study examined individuals with estrogen receptor–positive metastatic breast cancer treated with aromatase inhibitors. GLP-1 use was associated with better two-year overall survival and fewer hospitalizations. Notably, these patients also had lower risks of anemia, thrombocytopenia, and severe infections, without an apparent increase in gastrointestinal or cardiac toxicities.
A third, larger cohort study focused on patients with obesity across all stages of breast cancer. Over a median follow-up of nearly six years, GLP-1 use was linked to a marked reduction in all-cause mortality. The survival advantage was consistent regardless of age, body mass index, diabetes status, endocrine therapy type, or specific GLP-1 agent.
Together, these findings suggest a potential survival benefit that spans early, metastatic, and survivorship settings. However, all investigators emphasized that the observational design limits causal interpretation.
Direct antitumor effects—or metabolic benefit?
Whether GLP-1s influence breast cancer outcomes through direct effects on tumor biology or indirectly by improving metabolic health remains an open question.
Adding to the discussion, preclinical research presented at SABCS demonstrated that combining a GLP-1 agonist with radiotherapy in a mouse model of triple-negative breast cancer delayed tumor growth and extended survival compared with radiation alone. These findings support the hypothesis that GLP-1 signaling may interact with cytotoxic therapies to enhance antitumor responses.
Still, experts caution that preclinical and retrospective data are hypothesis-generating. Carefully designed prospective studies will be essential to clarify mechanism and magnitude of benefit.
Treatment tolerability: a double-edged sword
Beyond survival, several studies explored how GLP-1s may affect tolerance of breast cancer therapies, revealing a more complex picture.
In patients receiving endocrine therapy, GLP-1 use was associated with higher rates of certain side effects, including joint pain, hot flashes, mood symptoms, osteoporosis, and—less commonly—endometrial cancer. These findings raise concern, given that adverse effects already contribute significantly to endocrine therapy discontinuation.
Investigators suggested that GLP-1s’ effects on neuroendocrine pathways, weight loss, and gastrointestinal function may exacerbate some hormonal therapy–related symptoms. As a result, experts stressed the importance of individualized decision-making. For patients who tolerate endocrine therapy well, GLP-1s may still be appropriate; for others, they could worsen an already challenging treatment course.
Potential protection during chemotherapy
In contrast, GLP-1s appeared to confer unexpected benefits during chemotherapy. A large retrospective study found that patients using GLP-1s experienced significantly lower rates of a wide range of chemotherapy-related toxicities, including mucositis, neutropenia, thrombocytopenia, neuropathy, nausea, fatigue, cardiomyopathy, and sepsis.
The apparent reduction in peripheral neuropathy was particularly notable, as this toxicity frequently leads to dose reductions or treatment discontinuation. Interestingly, GLP-1 users also reported less nausea and vomiting—symptoms typically associated with GLP-1 therapy itself.
Because treatment-related toxicity is difficult to assess retrospectively, these findings require cautious interpretation. Nonetheless, they raise important questions about whether GLP-1s could play a supportive role during cytotoxic therapy, even among patients without diabetes or obesity.
Access and equity concerns
As enthusiasm grows, researchers are increasingly focused on who is—and is not—receiving GLP-1 therapy.
An analysis of more than 700,000 U.S. patients with breast cancer found that fewer than 8% had documented GLP-1 use. Uptake was higher among individuals with obesity but lower among older patients and those with advanced-stage disease. Differences also emerged by race, ethnicity, practice setting, and neighborhood-level social factors.
Lower use was observed among patients treated in community oncology practices, those living in areas with high rates of limited English proficiency, and individuals without access to telemedicine. These patterns raise concern that expanding indications for GLP-1s could widen existing disparities in cancer care.
Experts emphasize that equitable access must be prioritized as research continues, particularly if future trials confirm meaningful oncologic benefit.
Not a substitute for lifestyle intervention
Clinicians also caution against viewing GLP-1s as a stand-alone solution. Weight regain after discontinuation, loss of lean muscle mass, and variable long-term adherence highlight the importance of pairing pharmacologic therapy with exercise and nutrition interventions.
In future trials, experts advocate for standardized dosing, consistent drug selection, and integration of lifestyle programs, including resistance training, to preserve muscle mass and overall health.
The road ahead: prime time for trials
Despite lingering uncertainty, leaders in the field agree that the current evidence justifies prospective investigation. Several randomized and controlled studies are already underway or in development, although recruitment may be challenging given widespread off-label use and perceived benefit.
For now, the consensus is clear: GLP-1 receptor agonists show no signal of harm to breast cancer outcomes and may offer meaningful benefits across the disease continuum. Whether those benefits are sufficient to change clinical practice will depend on results from well-designed trials that address efficacy, safety, mechanism, and equity.
As one expert summarized, the signals emerging from breast cancer research are “intriguing and potentially practice changing”—but confirmation, not assumption, must guide the next chapter.
